Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.07
FSNUY's Cash to Debt is ranked higher than
57% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 0.19 vs. FSNUY: 0.07 )
FSNUY' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 0.07

Equity to Asset 0.41
FSNUY's Equity to Asset is ranked higher than
72% of the 307 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. FSNUY: 0.41 )
FSNUY' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.44
Current: 0.41

0.36
0.44
Interest Coverage 4.72
FSNUY's Interest Coverage is ranked higher than
69% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: 5.04 vs. FSNUY: 4.72 )
FSNUY' s 10-Year Interest Coverage Range
Min: 3.24   Max: 9999.99
Current: 4.72

3.24
9999.99
F-Score: 5
Z-Score: 1.40
M-Score: -2.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.02
FSNUY's Operating margin (%) is ranked higher than
86% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 8.52 vs. FSNUY: 14.02 )
FSNUY' s 10-Year Operating margin (%) Range
Min: 11.06   Max: 15.67
Current: 14.02

11.06
15.67
Net-margin (%) 4.97
FSNUY's Net-margin (%) is ranked higher than
77% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 4.94 vs. FSNUY: 4.97 )
FSNUY' s 10-Year Net-margin (%) Range
Min: 1.63   Max: 7.54
Current: 4.97

1.63
7.54
ROE (%) 7.88
FSNUY's ROE (%) is ranked higher than
73% of the 289 Companies
in the Global Medical Care industry.

( Industry Median: 10.03 vs. FSNUY: 7.88 )
FSNUY' s 10-Year ROE (%) Range
Min: 7.11   Max: 14.75
Current: 7.88

7.11
14.75
ROA (%) 3.20
FSNUY's ROA (%) is ranked higher than
74% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 3.52 vs. FSNUY: 3.20 )
FSNUY' s 10-Year ROA (%) Range
Min: 1.33   Max: 5.42
Current: 3.2

1.33
5.42
ROC (Joel Greenblatt) (%) 33.75
FSNUY's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 18.24 vs. FSNUY: 33.75 )
FSNUY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 32.75   Max: 66.61
Current: 33.75

32.75
66.61
Revenue Growth (3Y)(%) 4.80
FSNUY's Revenue Growth (3Y)(%) is ranked higher than
69% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. FSNUY: 4.80 )
FSNUY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -44.6   Max: 10.5
Current: 4.8

-44.6
10.5
EBITDA Growth (3Y)(%) 5.20
FSNUY's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 6.80 vs. FSNUY: 5.20 )
FSNUY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -48.9   Max: 24.5
Current: 5.2

-48.9
24.5
EPS Growth (3Y)(%) 13.80
FSNUY's EPS Growth (3Y)(%) is ranked higher than
77% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 13.80 vs. FSNUY: 13.80 )
FSNUY' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.7   Max: 34.9
Current: 13.8

-35.7
34.9
» FSNUY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with FSNUY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.10
FSNUY's P/E(ttm) is ranked higher than
88% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 44.70 vs. FSNUY: 21.10 )
FSNUY' s 10-Year P/E(ttm) Range
Min: 14.27   Max: 34.54
Current: 21.1

14.27
34.54
P/B 1.49
FSNUY's P/B is ranked higher than
88% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 2.93 vs. FSNUY: 1.49 )
FSNUY' s 10-Year P/B Range
Min: 0.41   Max: 3.06
Current: 1.49

0.41
3.06
P/S 1.05
FSNUY's P/S is ranked higher than
78% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. FSNUY: 1.05 )
FSNUY' s 10-Year P/S Range
Min: 0.38   Max: 1.07
Current: 1.05

0.38
1.07
PFCF 19.17
FSNUY's PFCF is ranked higher than
84% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 53.33 vs. FSNUY: 19.17 )
FSNUY' s 10-Year PFCF Range
Min: 3.67   Max: 83.14
Current: 19.17

3.67
83.14
EV-to-EBIT 13.67
FSNUY's EV-to-EBIT is ranked higher than
86% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 24.30 vs. FSNUY: 13.67 )
FSNUY' s 10-Year EV-to-EBIT Range
Min: 3.5   Max: 14.9
Current: 13.67

3.5
14.9
PEG 2.64
FSNUY's PEG is ranked higher than
91% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. FSNUY: 2.64 )
FSNUY' s 10-Year PEG Range
Min: 0.64   Max: 1.54
Current: 2.64

0.64
1.54
Shiller P/E 28.28
FSNUY's Shiller P/E is ranked higher than
87% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 2025.80 vs. FSNUY: 28.28 )
FSNUY' s 10-Year Shiller P/E Range
Min: 21.24   Max: 29.06
Current: 28.28

21.24
29.06
Current Ratio 1.32
FSNUY's Current Ratio is ranked higher than
72% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. FSNUY: 1.32 )
FSNUY' s 10-Year Current Ratio Range
Min: 0.98   Max: 1.57
Current: 1.32

0.98
1.57
Quick Ratio 0.99
FSNUY's Quick Ratio is ranked higher than
65% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. FSNUY: 0.99 )
FSNUY' s 10-Year Quick Ratio Range
Min: 0.75   Max: 1.21
Current: 0.99

0.75
1.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.73
FSNUY's Dividend Yield is ranked lower than
80% of the 183 Companies
in the Global Medical Care industry.

( Industry Median: 1.51 vs. FSNUY: 0.73 )
FSNUY' s 10-Year Dividend Yield Range
Min: 0.68   Max: 2.22
Current: 0.73

0.68
2.22
Dividend Payout 0.14
FSNUY's Dividend Payout is ranked higher than
97% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. FSNUY: 0.14 )
FSNUY' s 10-Year Dividend Payout Range
Min: 0.58   Max: 1.05
Current: 0.14

0.58
1.05
Dividend growth (3y) 13.80
FSNUY's Dividend growth (3y) is ranked higher than
87% of the 121 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. FSNUY: 13.80 )
FSNUY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 13.8
Current: 13.8

0
13.8
Yield on cost (5-Year) 0.91
FSNUY's Yield on cost (5-Year) is ranked lower than
73% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 2.10 vs. FSNUY: 0.91 )
FSNUY' s 10-Year Yield on cost (5-Year) Range
Min: 0.89   Max: 2.9
Current: 0.91

0.89
2.9
Share Buyback Rate -3.40
FSNUY's Share Buyback Rate is ranked higher than
64% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: -1.40 vs. FSNUY: -3.40 )
FSNUY' s 10-Year Share Buyback Rate Range
Min: -1.1   Max: -96.4
Current: -3.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.25
FSNUY's Price/DCF (Projected) is ranked higher than
85% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 4.02 vs. FSNUY: 1.25 )
FSNUY' s 10-Year Price/DCF (Projected) Range
Min: 0.36   Max: 1.26
Current: 1.25

0.36
1.26
Price/Median PS Value 1.87
FSNUY's Price/Median PS Value is ranked higher than
57% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. FSNUY: 1.87 )
FSNUY' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.72
Current: 1.87

0.7
1.72
Price/Peter Lynch Fair Value 1.50
FSNUY's Price/Peter Lynch Fair Value is ranked higher than
95% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. FSNUY: 1.50 )
FSNUY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.79   Max: 1.38
Current: 1.5

0.79
1.38
Earnings Yield (Greenblatt) 7.30
FSNUY's Earnings Yield (Greenblatt) is ranked higher than
85% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 4.60 vs. FSNUY: 7.30 )
FSNUY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.7   Max: 28.6
Current: 7.3

6.7
28.6
Forward Rate of Return (Yacktman) 15.91
FSNUY's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 12.92 vs. FSNUY: 15.91 )
FSNUY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.3   Max: 31.4
Current: 15.91

0.3
31.4

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, BDUUF, SKHCY » details
Traded in other countries:FRE.Germany, 0OO9.UK, FREN.Germany, 0QJF.UK, FRE.Switzerland,
Fresenius SE & Co KGaA is a health care company. It offers products and services for dialysis, hospitals, and outpatient medical care. It also manage projects and provide services for hospitals and other health care facilities worldwide. The Company's business segments are: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. Fresenius Medical Care offers products and services for patients with chronic kidney failure. Fresenius Kabi specializes in infusion therapies, intravenously administered drugs (IV drugs), and clinical nutrition. The company is also a supplier of medical devices and products in the area of transfusion technology. Fresenius Helios operated a total of 74 hospitals with more than 23,000 beds in Germany. Fresenius Vamed manages projects and provides services for hospitals and other health care facilities. The Company operates in about 80 countries through its subsidiaries.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK